EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Geldanamycins: Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy

Omeima Abdullah iD, Ziad Omran iD

International Journal of Molecular Sciences · 20.10.2024 · 25 (20) · 11293

DOI: 10.3390/ijms252011293 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.10.2024. Verfasst von Omeima Abdullah und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia. Hauptthemen laut MEDLINE: Benzoquinones, HSP90 Heat-Shock Proteins, Lactams, Macrocyclic, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Research, Development, and Innovation Authority (RDIA), Kingdom of Saudi Arabia, Research, Development, and Innovation Authority (RDIA), Kingdom of Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Geldanamycin, an ansa-macrolide composed of a rigid benzoquinone ring and an aliphatic ansa-bridge, was isolated from Streptomyces hygroscopicus. Geldanamycin is a potent heat shock protein inhibitor with remarkable antiproliferative activity. However, it shows pronounced hepatotoxicity in animal models and unfavorable pharmacokinetic properties. Four geldanamycin analogs have progressed through various phases of clinical trials, but none have yet completed clinical evaluation or received FDA approval. To enhance the efficacy of these Hsp90 inhibitors, strategies such as prodrug approaches or nanocarrier delivery systems could be employed to minimize systemic and organ toxicity. Furthermore, exploring new drug combinations may help overcome resistance, potentially improving therapeutic outcomes. This review discusses the mechanism of action of geldanamycin, its pharmacokinetic properties, and the various approaches employed to alleviate its toxicity and maximize its clinical efficacy. The main focus is on those derivatives that have progressed to clinical trials or that have shown important in vivo activity in preclinical models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoquinonesHSP90 Heat-Shock ProteinsLactams, MacrocyclicNeoplasmsHumansAnimalsAntineoplastic Agents

Stichwörter der Autor:innen

Hsp90PROTACansamycincancergeldanamycinmutasynthesis

Substanzen

BenzoquinonesHSP90 Heat-Shock ProteinsLactams, MacrocyclicgeldanamycinAntineoplastic Agents

Autor:innen und Institutionen

  • College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
  • King Abdullah International Medical Research Center, King Saud Bin Abdelaziz University for Health Sciences, Jeddah 21423, Saudi Arabia.

ORCID-Profile: Omeima Abdullah, Ziad Omran

Förderung

  • The Research, Development, and Innovation Authority (RDIA), Kingdom of Saudi Arabia
  • Research, Development, and Innovation Authority (RDIA), Kingdom of Saudi Arabia

Zitieren

APA

Abdullah, O., & Omran, Z. (2024). Geldanamycins: Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy. International Journal of Molecular Sciences, 25(20), 11293. https://doi.org/10.3390/ijms252011293

Vancouver

Abdullah O, Omran Z. Geldanamycins: Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy. International Journal of Molecular Sciences. 2024;25(20):11293. doi:10.3390/ijms252011293

BibTeX
@article{Abdullah2024,
  author = {Abdullah, Omeima and Omran, Ziad},
  title = {Geldanamycins: Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {20},
  pages = {11293},
  doi = {10.3390/ijms252011293}
}
Kostenlos starten →